SCHEMBL2685342

SCHEMBL2685342

CCOC(=O)CNC(Cc1ccc(F)c(F)c1)C(=O)c1cccc(-c2ccncc2)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR142 Q7Z601 1/20 0.47
▸ PPID Q08752 2/20 0.44
▸ AURKA O14965 3/20 0.41
▸ CTSV O60911 1/20 0.40
▸ CTSL P07711 1/20 0.40
▸ CTSS P25774 1/20 0.40
▸ F10 P00742 1/20 0.39
▸ PRSS1 P07477 1/20 0.39
▸ CYP17A1 P05093 1/20 0.38
▸ CYP21A2 P08686 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ ROCK1 Q13464 1/20 0.37
▸ CASP1 P29466 1/20 0.36
▸ S1PR3 Q99500 1/20 0.36
▸ SYK P43405 1/20 0.35
▸ MMEL1 Q495T6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2685336 1.00 GPR142 (0.47) GPR142PPIDAURKACTSVCTSL
Hydrochloric Acid SCHEMBL2687455 0.99 GPR142 (0.47) GPR142PPIDAURKACTSVCTSL
Hydrochloric Acid SCHEMBL2687459 0.99 GPR142 (0.47) GPR142PPIDAURKACTSVCTSL
SCHEMBL6028993 0.85 GPR142 (0.54) GPR142PPIDCYP17A1CYP11B1NAMPT
SCHEMBL2685590 0.76 GPR142 (0.78) GPR142PPIDCYP17A1CYP21A2CYP11B1
SCHEMBL2685584 0.76 GPR142 (0.78) GPR142PPIDCYP17A1CYP21A2CYP11B1
Hydrochloric Acid SCHEMBL2686615 0.76 GPR142 (0.77) GPR142PPIDCYP17A1CYP21A2CYP11B1
Hydrochloric Acid SCHEMBL2686611 0.76 GPR142 (0.77) GPR142PPIDCYP17A1CYP21A2CYP11B1
SCHEMBL2684833 0.76 GPR142 (0.67) GPR142PPIDCYP17A1CYP21A2CYP11B1
SCHEMBL2684830 0.76 GPR142 (0.67) GPR142PPIDCYP17A1CYP21A2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785468-B2 Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions AMGEN INC. (US) 2014-07-22 — — US disclosed
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2012-05-10 — — US disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115811-A1 PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS IAPP, INSR, AMY2A GPR142 2779/4885PPID 1033/4885AURKA 4636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback